Cellino Appoints Chris Gibson to Board of Directors

Audio By Carbonatix

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 24, 2024--

Cellino Biotech, Inc., a biotechnology company advancing autonomous, closed biomanufacturing for personalized regenerative medicines, today announced the appointment of Chris Gibson to the company’s Board of Directors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241024933617/en/

Chris Gibson, Ph.D., Co-Founder & CEO, Recursion. (Photo credit: Recursion)

Chris Gibson, Ph.D., is the Co-Founder and CEO of Recursion (NASDAQ:RXDX), a clinical-stage techbio company at the forefront of AI-driven drug discovery. Dr. Gibson has led a number of key partnerships for Recursion with leading pharma and tech companies, including Roche/Genentech, Bayer, and NVIDIA. Recursion’s recent proposed combination with Exscientia creates a robust AI-powered pipeline, with 10 clinical readouts expected in the next 18 months. Dr. Gibson also established the non-profit Recursion Foundation, which has incubated over a dozen companies and created a new generation of biotechnology founders, and personally mentors dozens of entrepreneurs to support the next wave of founder-CEOs.

“We are thrilled to welcome Chris to our board. As a seasoned founder and CEO, his hands-on experience and operational insights will be invaluable as we scale our team and vision for patient impact,” said Nabiha Saklayen, CEO & Co-Founder of Cellino. “The intersection of deep technology, biology, and medicine presents unprecedented opportunities and challenges. We are thrilled to have Chris’ experience on our board to provide Cellino with a perspective that is both visionary and deeply practical.”

“Cellino is driving the next wave of innovation in autonomous biomanufacturing,” said Gibson. “Cellino’s proprietary technology stack, including optical bioprocessing, closed cassettes, and image-guided co-pilots, has the potential to transform healthcare and bring potentially curative therapies to millions of patients. I look forward to working alongside Nabiha, the Cellino team, and the Board to make cell and tissue replacement therapies accessible to all.”

Autologous induced pluripotent stem cell-derived regenerative cell and tissue replacement therapies that utilize a patient’s own cells offer a promising avenue for addressing a variety of medical conditions. They minimize immune-related complications and are exceptionally well-suited to meet the needs of an aging and increasingly diverse patient population.

About Cellino

Cellino is building an ultra-scalable, autonomous, high precision biomanufacturing technology for personalized regenerative medicines. Learn more at www.cellinobio.com and follow Cellino on LinkedIn and X.

View source version on businesswire.com:https://www.businesswire.com/news/home/20241024933617/en/

CONTACT: Media:

Kimberly Ha

KKH Advisors

917-291-5744

[email protected]

KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: RESEARCH GENETICS CLINICAL TRIALS BIOTECHNOLOGY HEALTH PHARMACEUTICAL GENERAL HEALTH OPTICAL SCIENCE

SOURCE: Cellino Biotech, Inc.

Copyright Business Wire 2024.

PUB: 10/24/2024 08:00 AM/DISC: 10/24/2024 07:59 AM

http://www.businesswire.com/news/home/20241024933617/en